Ramipril & Hydrochlorothiazide Tablet
Description
MIPROOT-H
Ramipril 5 mg and Hydrochlorothiazide 12.5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Ramipril IP — 5 mg
Hydrochlorothiazide IP — 12.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
MIPROOT-H is a scientifically balanced antihypertensive combination of Ramipril 5 mg and Hydrochlorothiazide 12.5 mg, formulated for the effective management of hypertension and long-term cardiovascular and renal protection. This combination provides dual blood pressure control by combining the renin-angiotensin system inhibition of Ramipril with the diuretic action of Hydrochlorothiazide, resulting in superior antihypertensive efficacy and enhanced target organ protection.
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal function. Hydrochlorothiazide is a thiazide diuretic that increases sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances the antihypertensive effect of Ramipril.
MIPROOT-H is particularly beneficial in patients with uncontrolled hypertension, hypertension associated with diabetes, chronic kidney disease, obesity, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy.
Technical Knowledge of Ramipril and Hydrochlorothiazide
Ramipril is converted to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing aldosterone secretion, promoting vasodilation, improving endothelial function, and preventing adverse cardiovascular remodeling.
Hydrochlorothiazide acts on the distal convoluted tubule of the nephron by inhibiting sodium-chloride reabsorption, resulting in increased urinary excretion of sodium, chloride, and water. Long-term therapy reduces peripheral vascular resistance and contributes to sustained blood pressure reduction.
The combination of Ramipril and Hydrochlorothiazide provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits.
Mechanism of Action
Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, and protects cardiovascular and renal tissues.
Hydrochlorothiazide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, and enhances antihypertensive efficacy.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained blood pressure control
Supports cardiovascular and renal protection
Improves endothelial function
Reduces peripheral vascular resistance
Effective diuretic support
Suitable for long-term hypertension management under medical supervision
Clinical Applications
MIPROOT-H is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, hypertension with obesity, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Ramipril and Hydrochlorothiazide
Ramipril is an evidence-based ACE inhibitor with proven cardiovascular and renal protective benefits. Hydrochlorothiazide is a well-established thiazide diuretic with extensive clinical experience in hypertension management. The combination is widely recommended for patients requiring dual antihypertensive therapy because of its excellent efficacy, tolerability, and target organ protective effects.
Key Facts
ACE inhibitor and thiazide diuretic combination therapy
Ramipril 5 mg for cardiovascular and renal protection
Hydrochlorothiazide 12.5 mg for effective diuretic support
Provides sustained antihypertensive action
Effective in hypertension requiring combination therapy
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MIPROOT-H is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose MIPROOT-H for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 5 mg and Hydrochlorothiazide 12.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
MIPROOT-H from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril and Hydrochlorothiazide formulation.
